Alrijne Zorggroep Stichting

At Alrijne Zorggroep Stichting, cardiovascular research is a major focus, covering atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, peripheral arterial disease, and prevention after stroke. The studies are designed to test new treatments and prevention strategies that may lower the risk of major heart and vascular events, improve rhythm control, and support better long-term outcomes for people with complex cardiovascular conditions.

• Testing therapies that reduce the risk of heart attack, stroke, and cardiovascular death
• Improving treatment options for heart failure, atrial fibrillation, and vascular disease
• Evaluating strategies to prevent blood clots and other vascular complications

Research in this area also includes approaches for people with obesity and chronic kidney disease, reflecting a broad effort to improve care across linked cardiometabolic conditions.

The cancer research portfolio at this hospital includes studies in breast cancer, metastatic colorectal cancer, metastatic pancreatic cancer, multiple myeloma, chronic lymphocytic leukemia, and other solid tumors. These trials focus on assessing new treatment approaches, refining sequencing of therapy, and improving outcomes for patients with advanced or hard-to-treat cancers.

• Evaluating new anti-cancer therapies for advanced breast and other solid tumors
• Studying treatment timing and sequencing in metastatic cancers
• Exploring personalized approaches to improve disease control and survival

Much of the work aims to better match treatment intensity to patient needs while maintaining effectiveness and quality of life.

Neurology research at Alrijne Zorggroep Stichting includes studies in multiple sclerosis, secondary progressive multiple sclerosis, and prevention of recurrence after cryptogenic TIA or ischemic stroke. The trials are centered on improving disease control, testing individualized treatment schedules, and evaluating whether some long-term medicines can be adjusted safely without losing effectiveness.

• Assessing personalized treatment strategies for multiple sclerosis
• Studying safer ways to maintain control of inflammatory neurologic disease
• Testing whether stopping or continuing antiplatelet therapy best prevents recurrent stroke

This research aims to support more tailored care for people living with chronic neurologic conditions.

Trials in nutritional and metabolic diseases address obesity, diabetes-related ischemic ulcers, and patients with overlapping metabolic and cardiovascular risk. The main purpose is to evaluate treatments that can improve weight-related health, protect the heart and kidneys, and support healing in people with difficult-to-treat metabolic complications.

• Testing therapies for obesity linked to heart failure and atrial fibrillation
• Evaluating wound-related care for diabetes-associated ischemic ulcers
• Studying treatments that may reduce combined cardiovascular and kidney risk

These studies reflect a strong interest in the connections between metabolism, vascular health, and long-term disease prevention.

Respiratory research at this site includes work on chronic rhinosinusitis with nasal polyps. The trials are focused on improving symptom control, reducing polyp burden, and evaluating whether new targeted therapies can offer better relief for patients whose disease remains difficult to manage.

• Testing new treatments for persistent nasal polyps and congestion
• Evaluating symptom improvement in chronic upper airway disease
• Exploring options for patients with inadequately controlled respiratory inflammation

Although smaller in scale than the cardiovascular program, this area adds important breadth to the site’s clinical research portfolio.